Vera Therapeutics, Inc.
General ticker "VERA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.7B (TTM average)
Vera Therapeutics, Inc. follows the US Stock Market performance with the rate: 16.4%.
Estimated limits based on current volatility of 5.9%: low 36.96$, high 41.61$
Factors to consider:
- Total employees count: 112 (+119.6%) as of 2024
- Top business risk factors: Capital requirements, Regulatory and compliance, Product liability, Cybersecurity threats, Economic downturns and volatility
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [19.14$, 46.91$]
- 2025-12-31 to 2026-12-31 estimated range: [12.35$, 31.93$]
Financial Metrics affecting the VERA estimates:
- Negative: with PPE of -15.3 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -5.79 <= 0.33
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: Inventory ratio change, % of 0 <= 0
Short-term VERA quotes
Long-term VERA plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $90.90MM | $102.01MM | $167.17MM |
| Operating Income | $-90.90MM | $-102.01MM | $-167.17MM |
| Non-Operating Income | $1.85MM | $6.02MM | $15.02MM |
| Interest Expense | $0.99MM | $3.79MM | $7.63MM |
| R&D Expense | $68.99MM | $78.22MM | $126.17MM |
| Income(Loss) | $-89.06MM | $-95.99MM | $-152.15MM |
| Taxes | $0.00MM | $0.00MM | $0.00MM |
| Profit(Loss)* | $-89.06MM | $-95.99MM | $-152.15MM |
| Stockholders Equity | $76.91MM | $101.69MM | $577.15MM |
| Assets | $131.44MM | $175.55MM | $655.68MM |
| Operating Cash Flow | $-67.60MM | $-92.18MM | $-134.68MM |
| Capital expenditure | $0.06MM | $0.06MM | $0.97MM |
| Investing Cash Flow | $-70.55MM | $-39.43MM | $-425.03MM |
| Financing Cash Flow | $101.93MM | $133.54MM | $606.67MM |
| Earnings Per Share** | $-3.35 | $-2.25 | $-2.75 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.